EP3643309A1 — Medicaments for the treatment or prevention of fibrotic diseases
Assigned to Boehringer Ingelheim International GmbH · Expires 2020-04-29 · 6y expired
What this patent protects
The present invention relates to the use of indolinones of general formulasubstituted in the 6 position, whereinR<sub>1</sub>to R<sub>5</sub>and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable sal…
USPTO Abstract
The present invention relates to the use of indolinones of general formulasubstituted in the 6 position, whereinR<sub>1</sub>to R<sub>5</sub>and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.